Skip to main content

Table 4 Review of literature on SBRT

From: Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma

Authors

Study

Localization

Nr. of Lesions

Nr. of Fractions

Total Dose (Gy)

LC @ 1 year

Median OS (months)

Late Toxicity

Tse [34]

P

IHCC

EHCC

10

0

6

28-48

65%

15

1 biliary obstruction

1 bowel obstruction

Goodman [29]

P

IHCC

EHCC

5

0

1

18-30

77%

28.6

None

Polistina [28]

R

IHCC

EHCC

0

10

3

30a

80%b

35.5

1 ulceration

2 stenosis

Ibarra [35]

R

IHCC

EHCC

11

0

3

22-50

55.5%

11

3 Grad 3

Barney [36]

R

IHCC

EHCC

6

4

3-5

45-60

100%

15.5

1 Grade 3 biliary stenosis, 1 Grade 5 liver failure

Momm [22]

R

IHCC

EHCC

0

13

10-12

32-56

78%

33.5

1 Grade 3

5 cholangitis

Weiner [37]

P

IHCC

EHCC

12

0

5

40-55

91%§

13.2

1 hepatic failure§

1 biliary stricture

Kopek [27]

R

IHCC

EHCC

26

1

3

45

85%

10.6

6 ulcerations

3 stenosis

Mahadevan [30]

R

IHCC

EHCC

31

11

3-5

24-45

88%

17

4 Grade 3 (ulceration, cholangitis, abscess)

Sandler [26]

R

IHCC

EHCC

6

25

5

40

78%

15.7

5 Grade ≥ 3

Jung [25]

R

IHCC

EHCC

33

25±

1-5

15-60

85%

10

6 Grade 3 (ulceration, cholangitis, stenosis, perforation)

Current

R

IHCC

EHCC

17

26

3-12

21-66

78%

14

3 Grade ≥ 3

  1. R retrospective, P prospective, IHCCC intrahepatic cholangiocarcinoma, EHCCC extrahepatic cholangiocarcinoma
  2. aconcurrent Gemcitabine
  3. blocal response ratio
  4. ± 5 patients treated with conventional fractionation with a stereotactic boost
  5. §In this study SBRT was performed also in patients with hepatocellular carcinoma. LC and toxicities are reported for the whole group of patients including hepatocellular and cholangiocarcinoma